# ANNEX III

# LABELLING AND PACKAGE LEAFLET

# A. LABELLING

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**Box containing a vial of 20 ml or 50 ml**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Cyclix solution for injection (250 microgram/ml) for cattle

## 2. STATEMENT OF ACTIVE SUBSTANCES

Cloprostenol 250 µg/ml
as Cloprostenol sodium 263 µg/ml

## 3. PACKAGE SIZE

20 ml
50 ml

## 4. TARGET SPECIES

Cattle (cows)

## 5. INDICATION(S)

## 6. ROUTES OF ADMINISTRATION

Intramuscular use.

## 7. WITHDRAWAL PERIODS

Withdrawal period:
Meat and offal: 2 days
Milk: 0 hours

## 8. EXPIRY DATE

Exp. {mm/yyyy}
Once opened, use within 28 days.

Once broached, use by:

## 9. SPECIAL STORAGE PRECAUTIONS

Keep the vial in the outer carton.
Protect from light.

## 10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"

Read the package leaflet before use.

## 11. THE WORDS "FOR ANIMAL TREATMENT ONLY

For animal treatment only.

## 12. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

## 13. NAME OF THE MARKETING AUTHORISATION HOLDER

VIRBAC

## 14. MARKETING AUTHORISATION NUMBER(S)

Vm 05653/3009

## 15. BATCH NUMBER

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**Vial of 20 ml or 50 ml**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Cyclix

## 2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

250 µg/ml

## 3. BATCH NUMBER

Lot {number}

## 4. EXPIRY DATE

Exp. {mm/yyyy}

# B. PACKAGE LEAFLET

# PACKAGE LEAFLET:

## 1. Name of the veterinary medicinal product

Cyclix solution for injection (250 microgram/ml) for cattle

## 2. Composition

Each ml contains:

**Active substance:**
Cloprostenol 250 µg
as Cloprostenol sodium 263 µg

**Excipients:**
Benzyl alcohol (E1519) 20 mg

Colourless solution.

## 3. Target species

Cattle (cows).

## 4. Indications for use

Induction of luteolysis allowing resumption of oestrus and ovulation in cyclic females when used during dioestrus, synchronisation of oestrus (within 2 to 5 days) in groups of cyclic females treated simultaneously, treatment of suboestrus and uterine disorders related to a functioning or persistent corpus luteum (endometritis, pyometra), treatment of ovarian luteal cysts, induction of abortion until day 150 of pregnancy, expulsion of mummified foetuses, induction of parturition.

## 5. Contraindications

Do not use in pregnant animals, for which induction of abortion or parturition is not intended.
Do not use in animals with spastic diseases of the respiratory or gastrointestinal tract.
Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

## 6. Special warnings

Special precautions for safe use in the target species:
As with parenteral administration of any substance, basic aseptic rules should be observed. The injection site must be thoroughly cleaned and disinfected in order to reduce the risk of infection with anaerobic bacteria.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
People with known hypersensitivity to benzyl alcohol should avoid contact with the veterinary medicinal product. Do not eat, drink or smoke while handling the veterinary medicinal product. Direct contact with skin or mucous membranes of the user should be avoided. Prostaglandins of the $F_{2\alpha}$ type may be absorbed through the skin and may cause bronchospasm or miscarriage. The veterinary medicinal product must be handled carefully to avoid ACCIDENTAL SELF-INJECTION OR SKIN CONTACT. Pregnant women, women in childbearing age, asthmatics and persons with other respiratory tract diseases should exercise caution when handling cloprostenol. Those persons should wear rubber (or plastic) gloves during administration of the veterinary medicinal product. Accidental spillage on the skin should be washed immediately with soap and water.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:
Do not use in pregnant animals, for which abortion or induction of parturition is not intended. The veterinary medicinal product can be safely used during lactation.

Interaction with other medicinal products and other forms of interaction:
Concurrent use of oxytocin and cloprostenol increases effects on the uterus. The activity of other oxytocic agents can be increased after the administration of cloprostenol.
Do not use in animals being treated with non-steroidal anti-inflammatories, as the synthesis of endogenous prostaglandins is inhibited.

Overdose:
Therapeutic tolerance in cattle is broad. Overdoses of more than 10 times are generally well tolerated. Large overdoses may cause transient diarrhoea. No antidotes are available.
An overdose will not accelerate corpus luteum regression.

Major incompatibilities:
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

## 7. Adverse events

Cattle (cows):

| Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
|---|
| Anaphylactic-type reaction * |
| Undetermined frequency (cannot be estimated from the available data): |
| Injection site infection **<br>Retained placenta *** |

* Anaphylactic-type reactions can be observed which might be life threatening and require rapid medical care.
** Anaerobic infection if anaerobic bacteria penetrate the tissue at injection site, in particular following intramuscular injection.
*** When used for induction of parturition and dependent on the time of treatment relative to the date of conception, the incidence of retained placenta may be increased.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system <{national system details}.>

## 8. Dosage for each species, routes and method of administration

Intramuscular use.

For all indications, 0.5 mg cloprostenol/animal corresponding to 2 ml of the veterinary medicinal product, injected intramuscularly.

## 9. Advice on correct administration

In order to synchronise oestrus in groups of females, it is recommended that the veterinary medicinal product is administered on two occasions with a between treatment interval of 11 days.

## 10. Withdrawal periods

Meat and offal: 2 days
Milk: 0 hours

## 11. Special storage precautions

Keep out of the sight and reach of children.
Keep the vial in the outer carton.
Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label and the outer carton. The expiry date refers to the last day of that month.
Shelf life after first opening the immediate packaging: 28 days.

## 12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.
Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

## 13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

## 14. Marketing authorisation numbers and pack sizes

Cardboard box with 1 x 20 ml or 1 x 50 ml vial.

Not all pack sizes may be marketed.

## 15. Date on which the package leaflet was last revised

{MM/YYYY}
Detailed information on this veterinary medicinal product is available in the Union Product Database (*https://medicines.health.europa.eu/veterinary*).

## 16. Contact details

Marketing authorisation holder and manufacturer responsible for batch release:

VIRBAC
1ère avenue – 2065 m – LID
06516 Carros
FRANCE

Local representative(s) and contact details to report suspected adverse reactions:

Approved 13 July 2023